International Biotechnology Trust

Name
International Biotechnology Trust
Manager
SV Life Sciences Managers LLP
Type
Closed Ended Investment Company
ISIN
GB0004559349
Sector
Sector Specialist: Biotechnology & Healthcare
Launched
06/05/1994
OCF
1.27 %
Risk Rating
2
3 Year Sharpe
0.12
3 Year Alpha
-1.88
Yield
0 %
Benchmark
NASDAQ Biotechnology TR
Fund Size
£ 215.98 million
NAV
628
Gearing
96
Discount Premium
-6
The objective is to achieve long term capital growth by investing in high growth, development stage biotechnology companies that are either quoted or unquoted. The company invests in companies that are considered to be good value with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Holding %
Vertex Pharmaceuticals Inc 6.29 %
Gilead Sciences Inc 5.86 %
Amgen Inc 4.89 %
ACADIA Pharmaceuticals Inc 4.42 %
Neurocrine Biosciences Inc 4.41 %
Horizon Therapeutics PLC 4.34 %
Biogen Inc 4.17 %
Regeneron Pharmaceuticals Inc 3.33 %
Stemline Therapeutics Inc 3.15 %
Genmab A/S 2.88 %
Region %
United States 86.72 %
Europe - ex Euro 7.50 %
Sector %
Healthcare 100.00 %
Name
SV Life Sciences Managers LLP
Address
WB2B 6ST, London, United Kingdom
UCITS
No
Legal Structure
Closed Ended Investment Company

Managers

Carl Harald Janson
Joined 09/02/2013
Ailsa Craig
Joined 03/01/2008
Kate Bingham
Joined 11/01/2000

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.